Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05228210 · ClinicalTrials.gov registry record

Breast Cancer Self-Efficacy Scale for Partners

A clinical trial, sponsored by Indiana University.

Terminated
Registry status
25
Enrollment target

NCT05228210 is a clinical trial that was terminated before completion, run by Indiana University. The registered enrollment target is 25 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05228210 was terminated before completion, sponsored by Indiana University.

TERMINATED
Registry status
25 participants
Enrollment target

Study Summary

The concept of self-efficacy is a major predictor of physical, psychological, social and overall quality of life (QoL) among breast cancer survivors (BCS). Because survivor and partner outcomes are often linked, it is reasonable to hypothesize that self-efficacy is an important predictor of physical, psychological, social and overall QoL in partners as well. However, this hypothesis has yet to be tested, in part because no scale exists to measure cancer-related self-efficacy in partners. Development and psychometric testing of such a scale is a critical first step in developing a theoretical model predicting QoL in this population. Partners of BCS often report lower QoL compared to partners of healthy women, making them an important focus of research. During the award period, the applicant will follow standard instrument development procedures to develop the Breast Cancer Self-Efficacy Scale for Partners (BCSES-P) and test the scale's psychometric properties using a large and diverse sample of partners of breast cancer survivors.

Trial Details

FieldValue
Enrollment Target 25 participants
Start Date 2019-09-01
Est. Completion 2022-03-01

Sponsor

Indiana University

890 total trials

What the Registry Record Tells You About NCT05228210

The ClinicalTrials.gov registry entry for NCT05228210 describes a study currently listed as terminated, categorized as an unspecified phase. The registered enrollment target is 25 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Indiana University, which has 890 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 0 interventions.

NCT05228210 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT05228210 about?

NCT05228210 is a clinical study titled "Breast Cancer Self-Efficacy Scale for Partners". The concept of self-efficacy is a major predictor of physical, psychological, social and overall quality of life (QoL) among breast cancer survivors (BCS). Because survivor and partner outcomes are often linked, it is reasonable to hypothesize that self-efficacy is an important predictor of physical...

What is the current status of trial NCT05228210?

This trial is currently terminated. The enrollment target is 25 participants. The study started on 2019-09-01. Estimated completion is 2022-03-01.

Who is sponsoring clinical trial NCT05228210?

This trial is sponsored by Indiana University, which has 890 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.